Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

530613 IRAP Inhibitor, HFI-419 - CAS 1110650-72-0 - Calbiochem

A substrate competitive inhibitor of insulin-regulated aminopeptidase (IRAP) activity (Ki = 0.48 µM against 25 µM Leu-AMC).

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: (±)-Ethyl-2-acetamido-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, HFI419, Insulin-Regulated Aminopeptidase Inhibitor

Primary Target: IRAP
530613
Purchase on Sigma-Aldrich

Přehled

Replacement Information

Tabulka spec. kláve

CAS #Empirical Formula
1110650-72-0C₁₉H₁₈N₂O₅

Products

Katalogové čísloBalení ks/bal.
5.30613.0001 Skleněná láhev 10 mg
Description
OverviewThe racemic mixture of an aqueous soluble pyridinyl-4H-benzopyran compound that inhibits insulin-regulated aminopeptidase (IRAP) activity by competing against substrate for IRAP extracellular catalytic site binding (Ki = 0.48 µM against 25 µM Leu-AMC), while displaying little potency against glucose-6-phosphatase, aminopeptidae N, ACE1, leukotriene A4 hydrolase, or ER-associated aminopeptidases 1 & 2. Reported to boost 1 mM dibutyryl cAMP-evoked glucose uptake in cultured rat hippocampal slices (68% higher uptake with 100 nM HFI-419 than dbcAMP alone) in vitro and exhibit in vivo memory-enhancing efficacay in an object recognition test via direct cerebral lateral ventricle administration (0.1 or 1.0 nmol/2 µL/rat). HFI-419 is reported to hydrolyze into the less potent HFI-142 (Ki = 2.0 µM) after i.v. or i.p. injection in rats, although HFI-142 is more stable and likely exhibits better blood-brain permeability.
Catalogue Number530613
Brand Family Calbiochem®
Synonyms(±)-Ethyl-2-acetamido-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, HFI419, Insulin-Regulated Aminopeptidase Inhibitor
References
ReferencesMountford, S.J., et al. 2014. J. Med. Chem. 57, 1368.
Albiston, A.L., et al. 2011. Br. J. Pharmacol. 164, 37.
Albiston, A.L., et al. 2010. Mol. Pharmacol. 78, 600.
Albiston, A.L., et al. 2008. FASEB J. 22, 4209.
Product Information
CAS number1110650-72-0
FormOff-white powder
Hill FormulaC₁₉H₁₈N₂O₅
Chemical formulaC₁₉H₁₈N₂O₅
ReversibleY
Quality LevelMQ100
Applications
Biological Information
Primary TargetIRAP
Purity≥97% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
5.30613.0001 04055977260946

Documentation

IRAP Inhibitor, HFI-419 - CAS 1110650-72-0 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

References

Přehled odkazů
Mountford, S.J., et al. 2014. J. Med. Chem. 57, 1368.
Albiston, A.L., et al. 2011. Br. J. Pharmacol. 164, 37.
Albiston, A.L., et al. 2010. Mol. Pharmacol. 78, 600.
Albiston, A.L., et al. 2008. FASEB J. 22, 4209.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision06-June-2014 JSW
Synonyms(±)-Ethyl-2-acetamido-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, HFI419, Insulin-Regulated Aminopeptidase Inhibitor
DescriptionThe racemic mixture of an aqueous soluble (at least 50 µg/mL or 140 µM at pH 6.5) pyridinyl-4H-benzopyran compound that inhibits insulin-regulated (IRAP) aminopeptidase activity by competing against substrate for IRAP extracellular catalytic site binding (Ki = 0.48 µM; using 25 µM Leu-AMC as substrate) with concomitant interaction with active site zinc via its acetamide, while displaying little potency against glucose-6-phosphatase, aminopeptidase N, ACE1, leukotriene A4 hydrolase, or ER-associated aminopeptidases 1 & 2 (≤13% inhibition at 100 µM). Reported to boost 1 mM dibutyryl cAMP-evoked glucose uptake in cultured rat hippocampal slices (68% higher uptake in 5 min than dbcAMP alone without 100 nM HFI-419) in vitro and exhibit in vivo memory-enhancing efficacay in an object recognition test when administered directly into the cerebral lateral ventricle of rats via a cannula implant (0.1 or 1.0 nmol/2 µL/rat). HFI-419 is reported to hydrolyze into slightly less potent HFI-142 (Ki = 2.0 µM) after i.v. (plasma t1/2 = 11 min; 2 mg/kg) or i.p (plasma t1/2 = 4.6 h; 10 mg/kg) injection in rats, although HFI-142 is more stable and likely exhibits better blood-brain permeability (Blood:Brain HFI-142 ratio = 3.36 and 0.38, respectively, 0.5 and 4 h post single 3 mg HFI-419/kg i.v. injection).
FormOff-white powder
Intert gas (Yes/No) Packaged under inert gas
CAS number1110650-72-0
Chemical formulaC₁₉H₁₈N₂O₅
Purity≥97% by HPLC
SolubilityDMSO (100 mg/ml). Use only fresh DMSO for reconstitution.
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesMountford, S.J., et al. 2014. J. Med. Chem. 57, 1368.
Albiston, A.L., et al. 2011. Br. J. Pharmacol. 164, 37.
Albiston, A.L., et al. 2010. Mol. Pharmacol. 78, 600.
Albiston, A.L., et al. 2008. FASEB J. 22, 4209.